Maravai LifeSciences Holdings, Inc. (MRVI) stock
Close on Nov 12, 2026Market cap $1.99BP/E –Yield –
Maravai LifeSciences Holdings, Inc. grew revenue 10.7% to $213.00M over the twelve months to Sep 30, 2026. Free cash flow was -$13.27M. At the latest close the market valued the company at $1.99B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.99B
- P/E ratio
- –
- Price to sales
- 9.36
- Price to book
- 10.18
- Dividend yield
- –
- Free cash flow yield
- -0.67%
Fundamentals
- Revenue
- $213.00M
- Net income
- -$65.67M
- EPS, diluted
- -$0.44
- Free cash flow
- -$13.27M
- Book value per share
- $1.31
- Diluted shares
- 149M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $7.70
- Open
- $7.93
- Day's range
- $7.60 – $7.93
- Volume
- 2,504,484
- Average volume (20 days)
- 2,217,364
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Nov 2020)
- Beta (5 years)
- 1.02
- 52-week range
- $2.80 – $9.42
- RSI (14 days)
- 51.5
- Volatility (1 year)
- 70.6%
- Relative volume
- 0.82×
- WACC
- 10.1%
On 1 of our idea list: Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | MRVI | S&P 500 | Difference | MRVI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +8.8% | -2.7% | +11.5 pts | ||
| 3 months | +32.9% | -1.7% | +34.6 pts | ||
| Year to date | +136.3% | +11.9% | +124.4 pts | ||
| 1 year | +136.3% | +12.0% | +124.3 pts | ||
| 3 years | +49.7% | +78.2% | −28.5 pts | +14.4% | +21.2% |
| 5 years | -79.6% | +73.2% | −152.8 pts | -27.2% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Maravai LifeSciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Results
About Maravai LifeSciences
Pharmaceutical Preparations
Maravai LifeSciences Holdings provides products and services that support the development of drug therapies, vaccines, and diagnostics, as well as human disease research. The business operates through two primary segments: TriLink and Cygnus. The TriLink segment supplies modified nucleic acids and associated technologies, including messenger RNA, CleanCap capping reagents, ModTail modifications, oligonucleotides, nucleoside triphosphates, specialty enzymes, and contract synthesis services. The Cygnus segment focuses on biologics safety testing solutions, offering host cell protein detection kits, viral clearance prediction assays, auxiliary reagents, and custom analytical testing. Its client base spans biopharmaceutical corporations, emerging biotechnology enterprises, academic and life science research institutions, and diagnostic organizations.
Company profile, executives and historyMaravai LifeSciences stock: common questions
What is Maravai LifeSciences's stock price?
MRVI closed at $7.68 on Nov 12, 2026, down 0.26% on the day. Over the past 52 weeks it traded between $2.80 and $9.42.
What is Maravai LifeSciences's market cap?
Maravai LifeSciences was worth $1.99B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is MRVI's P/E ratio?
Maravai LifeSciences lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.44), so it has no meaningful P/E ratio.
How much revenue does Maravai LifeSciences make?
Maravai LifeSciences reported revenue of $213.00M for the twelve months to Sep 30, 2026, up 10.7% from a year earlier.
Does Maravai LifeSciences pay a dividend?
No. Maravai LifeSciences has not paid a cash dividend over the last twelve months.
When does Maravai LifeSciences report earnings next?
Maravai LifeSciences's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has MRVI stock performed over the past year?
Including dividends, MRVI returned +136.3% over the past year, against +12.0% for the S&P 500.
How many MRVI shares are sold short?
14M shares were sold short at the latest FINRA report, 11.75% of the float, or 6.8 days of average trading volume.
Who are Maravai LifeSciences's competitors?
Companies most similar to Maravai LifeSciences by business, industry and size include CYRX, KMDA, LFCR, LGND, AMRN.
See a number that looks wrong?